Hemocompatibility Screening via Fibrinogen Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current analytical technologies for assessing the conformational changes of adsorbed fibrinogen on medical device materials are complex, expensive, time-intensive, and lack sensitivity, making them unsuitable for high-throughput biomaterial screening.
Innovation Solution
A method involving the contact of candidate materials with fibrinogen and thrombin to measure fibrinogen cleavage products, such as fibrinopeptide A and B, as a surrogate marker for conformational changes, which predicts material hemocompatibility, allowing for high-throughput screening and identification of hemocompatible materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current analytical technologies are used to assess conformational changes of adsorbed fibrinogen, then measurement precision is achieved, but device complexity and time consumption increase significantly
Solution Approach 1:
The patent extracts and measures only the critical cleavage products (fibrinopeptide A and fibrinopeptide B) resulting from thrombin action on adsorbed fibrinogen, rather than attempting to directly assess complex conformational changes. This extraction of key measurable parameters simplifies the assay while maintaining detection sensitivity for hemocompatibility assessment
Solution Approach 2:
The patent introduces thrombin as an intermediary enzyme that converts difficult-to-measure conformational changes into easily quantifiable cleavage products. Thrombin acts as a mediator that transforms the complex structural information of adsorbed fibrinogen into simple peptide fragment measurements, resolving the contradiction between measurement precision and assay complexity
2Measurement precision
If current analytical technologies are used to assess conformational changes, then measurement precision is improved, but time consumption increases
Solution Approach 1:
The patent performs preliminary adsorption of fibrinogen onto the test material surface before adding thrombin. This preliminary action allows the fibrinogen to adopt its conformational state on the material surface, which is then locked in and measured through subsequent thrombin cleavage. This approach enables rapid assessment without requiring prolonged direct measurement of conformational changes
Solution Approach 2:
The patent replaces complex mechanical or structural analysis methods with a biochemical assay system. Instead of using sophisticated instruments to directly probe fibrinogen conformation, the system uses enzymatic cleavage and simple product detection, dramatically reducing assay time while maintaining precision through the specific biochemical response to conformational changes
3Measurement precision
If current analytical technologies are used, then conformational changes can be detected, but productivity for high-throughput screening decreases
Solution Approach 1:
The patent segments the complex conformational analysis into discrete, independent steps: fibrinogen adsorption, thrombin addition, and cleavage product measurement. Each step can be performed in parallel across multiple samples, enabling high-throughput screening while maintaining the ability to detect conformational changes through the cumulative effect on cleavage products
Solution Approach 2:
The patent changes the measurement parameter from direct conformational assessment to quantification of cleavage product concentration. This parameter transformation enables simple, rapid measurement using standard spectroscopic or immunoassay methods, dramatically increasing screening throughput while preserving detection sensitivity through the specific biochemical response to conformational changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a sensitive and robust method for evaluating material hemocompatibility, correlating fibrinogen cleavage product levels with platelet adhesion and thrombosis risk, enabling the development of medical devices with reduced thrombosis and platelet adhesion.
Implementation Method 1
fibrinogen adsorption as compared to a material that is not hemocompatible
Implementation Method 2
cleaving the fibrinogen with thrombin to yield a fibrinogen cleavage product
Data Source
AI summary
Provided herein are techniques for screening materials for hemocompatibility. Hemocompatible materials may be advantageous when incorporated into devices that may come into direct contact with blood or other bodily fluids. Such techniques take advantage of conformational changes in fibrinogen when adsorbed onto certain materials. As a result of conformational changes, the fibrinogen has altered responsiveness to cleavage by thrombin. Accordingly, the products of thrombin cleavage of fibrinogen may be assessed to determine the hemocompatibility of a material.